- Home
- FDMT vs INBX Comparison
FDMT vs INBX Comparison
Compare FDMT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FDMT | INBX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 430.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FDMT | INBX |
|---|---|---|
| Price | $7.21 | $76.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $30.33 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 254.4K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $120,000.00 | ★ $1,400,000.00 |
| Revenue This Year | $21,181.08 | $563.00 |
| Revenue Next Year | $162.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 605.88 | N/A |
| 52 Week Low | $2.24 | $10.81 |
| 52 Week High | $12.34 | $94.57 |
Technical Indicators
Market Signals| Indicator | FDMT | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 47.85 |
| Support Level | $6.96 | $74.46 |
| Resistance Level | $11.81 | $82.34 |
| Average True Range (ATR) | 0.68 | 5.92 |
| MACD | -0.18 | -1.19 |
| Stochastic Oscillator | 4.95 | 18.35 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.